The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

Healthcare stocks see mixed performance as Dr Lal Pathlabs and Aurobindo Pharma rise over 2% after CLSA upgrades their ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

There is mild anticipation that as the Snake year slithers in, the local IPO markets will open up, and the STI will hit a new ...

Taking a more bearish stance, CLSA has downgraded HUL to an Underperform rating. The brokerage firm also has slashed its ...

Out of the 43 analysts that now have coverage on HUL, 27 of them have maintained a 'Buy' rating on the stock, while 13 of ...

SK Hynix Inc. reported a record quarterly profit after the company extended its lead in advanced memory chips for datacenters ...

The third-quarter earnings season is in full swing, with around 59 companies set to release their results on Thursday.

BYD COMPANY (01211.HK) toppled Toyota for the first time in 2024 to become the most popular car brand in Singapore, foreign ...

Confusion among strategists evidenced by outlook for interest rates; S-REITs staying lethargic; data centres in focus ...